The GLP-1 receptor antagonist exendin-9-39 (avexitide), which blocks the effect of GLP-1, decreasing insulin secretion and mitigating hypoglycemia, has shown promising results in patients with post bariatric hypoglycemia (49). Here, INS is linked to Hypoglycemia.